SEC Form 4 · accession 0000899243-18-002284

ARMO BioSciences, Inc. · ARMO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Beth C Seidenberg

Director · 10% Owner

Period of report

Jan 30, 2018

Accepted (ET)

Jan 30, 2018 · 5:10 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001693664

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3,F4	Jan 30, 2018	C	4,266,683	—	A	4,266,683	I	By KPCB Holdings, Inc., as nominee

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-1 Convertible Preferred Stock^F3,F4,F2	—	Jan 30, 2018	C	673,173	D	—	—	Common Stock	673,173	I
Series A Convertible Preferred Stock^F3,F4,F2	—	Jan 30, 2018	C	1,212,494	D	—	—	Common Stock	1,212,494	I
Series B Convertible Preferred Stock^F3,F4,F2	—	Jan 30, 2018	C	1,296,248	D	—	—	Common Stock	1,296,248	I
Series B-1 Convertible Preferred Stock^F3,F4,F2	—	Jan 30, 2018	C	355,429	D	—	—	Common Stock	355,429	I
Series C Convertible Preferred Stock^F3,F4,F2	—	Jan 30, 2018	C	403,097	D	—	—	Common Stock	403,097	I
Series C-1 Convertible Preferred Stock^F3,F4,F2	—	Jan 30, 2018	C	326,242	D	—	—	Common Stock	326,242	I

Explanation of responses

F1The total represents shares received upon conversion of shares of Series A-1, A, B, B-1, C and C-1 Convertible Preferred Stock.
F2Each share of Series A-1 Convertible Preferred Stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock, Series C Convertible Preferred Stock and Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date.
F3Consists of 3,475,576 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XIV, LLC ("KPCB XIV"), 294,029 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XIV Founders Fund, LLC ("KPCB XIV FF"), 480,625 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 16,453 shares of common stock issuable upon the deemed conversion of shares of the Issuer's preferred stock held by KPCB XVI Founders Fund, LLC ("KPCB XVI FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee" for the accounts of such entities. The managing member of KPCB XIV and KPCB XIV FF is KPCB XIV Associates, LLC ("KPCB XIV Associates").
F4(Continued from Footnote 3) Brook Byers, L. John Doerr, William Gordon and Theodore Schlein, the managing members of KPCB XIV Associates, and Dr. Beth Seidenberg, a member of KPCB XIV Associates, exercise shared voting and dispositive control over the shares held by KPCB XIV and KPCB XIV FF. The managing member of KPCB XVI and KPCB XVI FF is KPCB XVI Associates, LLC ("KPCB XVI Associates"). L. John Doerr, Eric Feng, Wen Hsieh, Randy Komisar, Dr. Beth Seidenberg and Theodore Schlein, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and KPCB XVI FF.